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Objective: This study assessed predictive factors for reintervention after thoracic endovascular aortic repair (TEVAR) for
complicated aortic dissection (C-AD).
Methods: An institutional review of consecutive TEVAR for C-AD was performed.
Results: Between 2000 and 2011, 41 patients underwent TEVAR for a C-AD involving the descending thoracic aorta.
Primary indications included aneurysm >55 mm in 24, rapid aneurysmal enlargement or impending rupture in 6, saccular
aneurysm >20 mm in 1, malperfusion in 1, intractable chest pain in 3, and rupture in 6. Technical success was achieved in
100%. The 30-day mortality rate was 5% (n[ 2). Fourteen secondary procedures were performed in 13 patients (32%) for
indications of device migration in 2, proximal type I endoleak in 5, distal type I endoleak in 2, type II endoleak in 1,
aneurysmal evolution of the descending thoracic aorta in 2, aneurysmal expansion of the dissected abdominal aorta in 1,
and retrograde dissection in 1. Multivariate analysis demonstrated that oversizing$20% (odds ratio [OR], 16; P[ .011),
bare-spring stent in the proximal landing zone of the stent graft (OR, 12; P[ .032), and anticoagulant therapy (OR, 78;
P [ .03) were signiﬁcant factors for reintervention. On univariate analysis, large aneurysm was a risk factor for rein-
tervention (P [ .002), whereas complete false lumen thrombosis at the stent graft level was protective (P < .05).
Conclusions: This study conﬁrms the feasibility of TEVAR for C-AD, although the rate of reintervention is high. Excessive
oversizing, a bare-spring stent graft in the proximal landing zone, large aortic dilatation, and anticoagulant therapy were
factors associated with reintervention. Complete false lumen thrombosis at the stent graft level was protective. (J Vasc
Surg 2014;59:327-33.)Initially designed to treat degenerative aneurysms,
thoracic endovascular aortic repair (TEVAR) was intro-
duced as an alternative minimally invasive procedure for
the treatment of complicated aortic dissection (C-AD) in
1999.1 Endovascular repair works by covering the proximal
tear, thus reducing or preventing ﬂow in the false lumen
and thereby allowing true lumen expansion. As a conse-
quence of lower perioperative morbidity and mortality
compared with open surgery, consensus has now shifted
such that many now consider TEVAR as the ﬁrst-line
therapy for C-AD.2,3
However, the long-term durability of this endovascular
approach is still being debated. Some reports suggest a high
rate of reintervention4-6 of up to 46% in the acute setting.7
This has raised concerns regarding the long-term outcomes
and costs of TEVAR for C-AD. Recent cost-effectiveness
analyses have demonstrated that the postintervention costs
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dures.8 It is important that signiﬁcant clinical and technical
factors associated with secondary intervention are identiﬁed
and mechanisms of failure elucidated so that we may
prevent and manage them in future. Published data in
this area have been lacking.
The aim of our study was to identify the risk factors for
reintervention after TEVAR for the treatment of C-AD
involving the descending thoracic aorta.
METHODS
The Institutional Review Board approved this study,
and informed consent was obtained from each participant.
Patients selection and follow-up. The study included
all consecutive patients undergoing TEVAR for C-AD,
deﬁned as aortic aneurysm >55 mm, rapid aneurysmal
enlargement or impending rupture (>5mmover 6months),
rupture, saccular aneurysm >20 mm, malperfusion
syndrome, or intractable chest pain under medical therapy
involving the descending thoracic aorta between October
2000 and December 2011 at our unit.
Aortic dissection was deﬁned as chronic 14 days after
onset of acute symptoms. According to the Reporting
Standards For Thoracic Endovascular Aortic Repair,9 tech-
nical success was deﬁned as complete coverage of the
primary entry tear without a type I leak at the end of the
procedure.
Patients were preoperatively evaluated with respect to
age, sex, smoking, obesity, hypertension, diabetes, long-
term anticoagulant therapy, renal insufﬁciency, history of
ascending or abdominal aortic repair, and according to327
Table I. Clinical and demographic characteristics of the
41 patients at the initial procedure
Characteristicsa All patients (N ¼ 41)
Age, years 66 6 11
Male sex 34 (83)
Hypertension 31 (76)
Diabetes 2 (5)
Smoker 18 (44)
Coronary artery disease 6 (15)
Dyslipidemia 5 (12)
COPD 9 (22)
Renal insufﬁciency 2 (5)
Obesity 6 (15)
Prior aortic surgery 16 (39)
Corticosteroid therapy 5 (12)
Anticoagulant therapy 5 (12)
Marfan syndrome 1 (2)
ASA classiﬁcation
2 16 (39)
3 22 (54)
4 3 (7)
ASA, American Society of Anesthesiologists; COPD, Chronic obstructive
pulmonary disease.
aContinuous data are shown as mean 6 standard deviation and categoric
data as number (%).
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Classiﬁcation. They were prospectively monitored by sched-
uled clinical observation and with contrast-enhanced
computed tomography (CT) preoperatively, before hospital
discharge, at 1, 3, 6, and 12 months, and annually there-
after. All aortic CTmeasurements were taken in a perpendic-
ular plane using centerline reconstructions. Preoperative
and postoperative measures included neck diameter and
length for device sizing, maximal aortic diameter, and aortic
diameters at the levels of the proximal thoracic aorta (2 cm
below the left subclavian artery ostium), the midthoracic
aorta (at the level of the left inferior pulmonary vein),
the celiac artery, and both renal arteries. Extension of the
dissection above or below the celiac axis and false lumen
status at the level of the stent and more distally were also
analyzed. The number of visceral and renal vessels perfused
by the false lumen was also reported, but we did not analyze
that variable in terms of reintervention.
With regards to outcomes, patients were grouped by
those with and without reintervention. Reintervention
was deﬁned as any intervention after the original procedure
that was related to the dissection or a complication of the
original procedure.
Endovascular device and procedural details. All
endovascular procedures were performed in an operating
theater under general anesthesia. Open femoral cutdowns
were used to facilitate catheter-based access to the true
lumen and the aortic arch. Transesophageal echocardiog-
raphy was frequently used to verify the position of the
guidewire in the true lumen. Angiograms were performed
before stent graft deployment to clearly delineate the
proximal tear site and after deployment to conﬁrm entry
tear sealing and absence of endoleak. For patients with
a short proximal landing zone (<20 mm), hybrid opera-
tions, combining extra-anatomic debranching of the supra-
aortic vessels with immediate endovascular stent graft
deployment, were performed to enable coverage of the
proximal entry tear.
During the period of study inclusion, ﬁve different
stent grafts were implanted, comprising the Thoracic
Excluder and C-TAG (W.L. Gore and Associates, Flagstaff,
Ariz), Talent and Valiant (Medtronic, Santa Rosa, Calif),
and Zenith TX2 (Cook, Bloomington, Ind). Stent graft
selection was at the discretion of the surgeon. For the anal-
ysis, the stent grafts were grouped depending on the pres-
ence of a proximal bare spring: The Excluder, the C-TAG,
and the TX2 were classiﬁed as “membrane-covered prox-
imal-spring,” and the Valiant and the Talent as “proximal
bare-spring” stent grafts.
Statistical analysis. All primary procedural, reinter-
vention, and outcomes data were prospectively collected
in a vascular registry. Patients who did and did not undergo
reinterventions were compared. Univariate and multivar-
iate logistic regressions were performed to assess the inﬂu-
ence of initial variables on the occurrence of reintervention.
Variables of initial characteristics signiﬁcantly associated with
reintervention by univariate logistic regression (P < .05)
were entered into the model. Postoperative false lumenthrombosis was considered as a variable of follow-up and
was not analyzed in the multivariate logistic regression. This
variable was analyzed separately. The multivariate model
was built by a step-down procedure. The adjusted odds
ratios (ORs) and 95% conﬁdence intervals (CIs) were
calculated. Univariate and multivariate logistic regressions
were performed with the Firth penalized likelihood method
because somemodels had quasi-complete separation of data
and the results of logistic regression with maximum likeli-
hood estimates are unreliable for small samples. A P value
of <.05 was considered statistically signiﬁcant. All statistical
analyses were performed at the Clinical Research and
Epidemiology Department of the Centre Hospitalier Uni-
versitaire Montpellier with SAS 9 software (SAS Institute
Inc, Cary, NC).
RESULTS
Patient demographics. Between October 2000 and
December 2011, 41 patients underwent stent graft place-
ment for a C-AD involving the descending thoracic aorta.
Patients characteristics are reported in Table I. The patients
were a median age of 66 years (range, 42-94 years), with
a male-to-female ratio of 4.9:1. Dissection characteristics
are reported in Table II. The median interval from the
initial dissection to stent graft repair was 1.5 months
(interquartile range, 0.3-36 months). The dissection was
treated at the acute phase in 15 patients and at the chronic
phase in 26. The indication for repair included aneurysm
>55 mm in 24, rapid aneurysmal enlargement or
impending rupture (>5 mm over 6 months) in 6, saccular
aneurysm >20 mm in 1, malperfusion syndrome in 1,
intractable chest pain under medical therapy in 3, and
rupture in 6.
Table II. Morphologic characteristics of the dissection
of the 41 patients at the initial procedure
Characteristicsa All patients (N ¼ 41)
Acute 15 (37)
Aneurysm >55 mm 2
Rapid aneurysmal enlargement 3
Malperfusion syndrome 1
Intractable chest pain 3
Rupture 6
Chronic 26 (63)
Aneurysm >55 mm 22
Saccular aneurysm >20 mm 1
Rapid aneurysmal enlargement 3
Proximal entry tear
Zone 2 10 (24)
Zone 3 31 (76)
Extensive dissectionb 35 (85)
Maximal aortic diameter, mm 57 6 17
Proximal landing zone
Length, mm 27 6 9
Diameter, mm 30.7 6 5.5
aContinuous data are shown as mean 6 standard deviation and categoric
data as number (%).
bExtending into the abdominal aorta vs limited dissection, deﬁned as
restricted to the thoracic aorta.
Table III. Details of the initial procedure of the 41
patients
Initial interventiona All patients (N ¼ 41)
Left subclavian artery coverage 18 (44)
With debranching of the SAV 16 (39)
Proximal oversizing $20% 11 (27)
Stent graft with proximal bare spring 9 (22)
Length of aortic coverage, cm 18 6 7
SAV, Supra-aortic vessels.
aContinuous data are shown as mean 6 standard deviation and categoric
data as number (%).
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proximal entry tear was in zone 2 in 10 (24%) and in zone
3 in 31 (76%). The dissection extended to the abdominal
aorta in 35 (85%) and was restricted to the thoracic aorta
in 6 (15%). The branch vessels arising from the false lumen
were the left renal artery in 13 patients (32%), the right
renal artery in 7 (17%), the celiac trunk in 7 (17%), and
the superior mesenteric artery in 8 (20%).
Prior aortic surgery in 14 patients including 10 with
prior type A dissection or arch repair and two each with
open abdominal aortic aneurysm repair and aortobifemoral
bypass.
Procedural outcomes. Details of the initial procedure
of the 41 patients are reported in Table III. The stent grafts
implanted at the initial TEVAR included those without
a proximal bare spring in 32 patients (Thoracic Excluder
stent grafts in 13 patients, redesigned and renamed “TAG”
stent grafts in 15, and TX2 stent grafts in four) and with
a proximal bare spring in nine (Valiant in eight and Talent
in one). Deployment of two stent grafts was required in 11
patients at the initial procedure to increase the length of
coverage. Technical success, deﬁned as sealing of the
primary entry tear without residual endoleak at the end of
the procedure, was achieved in all patients.
Device diameters ranged from 28 to 46 mm. The mean
proximal landing zone diameter was 30.73 mm (range, 23-
36 mm), median proximal oversizing was 14.71% (range,
8.8%-33.3%), and median length of aortic coverage was
15 cm (range, 9-31.5 cm).
Sixteen (39%) hybrid operations combining extra-
anatomic debranching of the supra-aortic vessels concomi-
tant with TEVAR were required because of inadequateproximal landing zone (<20 mm) for a total endovascular
solution. Also performed were 12 partial-arch debranch-
ing procedures through cervical access and four total
arch debranching procedures with ascending aorta-
based bypass grafts to all of the arch branches through
sternotomy.
Intraoperative complication in four patients (10%)
included, in one patient each:
d Rupture of the right external iliac artery treated with
successful deployment of a covered stent (Wallgraft
10-70);
d Device misplacement and inadequate seal of the
primary entry tear with an associated proximal type I
endoleak on aortogram due to a tortuous seal zone
anatomy, despite a previous total debranching of the
supra-aortic trunks and required the successful deploy-
ment of an additional proximal stent graft;
d Migration of the stent graft 5 cm caudally that was
successfully treated by additional proximal stent graft
placement; and
d Unintentional partial endograft coverage of the left
common carotid artery successfully treated by stenting
the origin of the left common carotid artery.
Follow-up outcomes. The median follow-up was
12.2 months (range, 3 days-8 years). Early causes of major
adverse events and death after the initial TEVAR are re-
ported in Table IV. Prolonged reversible ischemic neuro-
logic deﬁcit ($24 hours to #7 days) occurred in three
patients. One patient required cerebrospinal ﬂuid drainage.
The incidence of permanent paraplegia and renal insufﬁ-
ciency requiring dialysis (>30 days) was 2% (n¼ 1) and 0%,
respectively. No late deaths (>30 days) were attributed to
the primary TEVAR procedure.
One patient died of decompensated cirrhosis 20 days
after reintervention, and another patient died of a Stanford
type A aortic dissection 20 months after reintervention. No
renal or neurologic complication occurred.
The overall mortality rate was 10% (n ¼ 4). The
median survival time without reintervention was
61.9 months (95% CI, 24.6-1) after TEVAR (Fig).
CT ﬁnding on follow-up. Complete false lumen
thrombosis at 1 year was 85% (n ¼ 35) in the region of
Table IV. Early (<30 days) major outcomes after initial
endovascular thoracic aortic repair (TEVAR)
Outcome
Secondary
intervention
(n ¼ 13)
No
reintervention
(n ¼ 28)
Total
(n ¼ 41)
Death
Thoracic aortic
rupture
0 1 1
Mesenteric
ischemia
0 1 1
PRIND 2 1 3
Spinal cord injury 0 1 1
Renal failurea 2 1 3
Pulmonary failureb 1 1 2
Debranching
cervical access
site
complications
2 3 5
PRIND, Prolonged reversible ischemic neurologic deﬁcit.
aRequiring dialysis.
bRequiring postoperative reintubation.
Fig. Kaplan-Meier analysis for survival without reintervention for
thoracic aortic endovascular repair (TEVAR) is shown with the
95% conﬁdence interval (CI) (gray lines).
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stented aorta. Complete false lumen thrombosis at the
stent graft level was signiﬁcantly higher in the “no reinter-
vention” group (96% [n ¼ 25]) than in the “reinterven-
tion” group before reintervention (54% [n ¼ 7]; P ¼
.003). At the end of the follow-up, complete false lumen
thrombosis at the stent graft level was 96% (n ¼ 25) in the
“no reintervention” group and 77% (n ¼ 10) after rein-
tervention in the “reintervention” group, but the differ-
ence was not signiﬁcant.
Including the whole study population, favorable aortic
remodeling, deﬁned as stabilization or regression of the
false lumen diameter, was demonstrated in 39 patients
(95%), and complete aortic remodeling, deﬁned as
complete reattachment of the dissecting membrane, was
noted in four patients (10%). After the primary interven-
tion, an increase in aortic diameter (>5 mm) in the region
of the stented aorta occurred in eight patients (20%),
which was attributable to type I endoleaks in two patients
and to persistent retrograde ﬂow in the false lumen
through distal fenestrations in the other six. All of these
patients underwent a reintervention. After the secondary
procedure, only one patient still had an increase in the
maximal aortic diameter despite a complete false lumen
thrombosis.
Reintervention. Fourteen reinterventions were per-
formed in 13 patients (32%), the indications for which
included device migration in 2, proximal type I endoleak
in 5, distal type I endoleak in 2, type II endoleak in 1,
aneurysmal degeneration of the descending thoracic aorta
below the stent graft in 1 and above the stent graft in 1,
and aneurysmal expansion of the dissected abdominal
aorta in 1. One patient required a third procedure for
a retrograde dissection. The median delay to reinterven-
tion after implantation was 6.3 months (range, 7 days-
7.3 years).Reinterventions consisted of 13 endovascular interven-
tions (93%): additional proximal endografting in nine
(65%), requiring transposition of the supra-aortic vessel
in four (29%), and additional distal endografting in six
(43%). Among them, two patients underwent additional
proximal and distal endografting. One (2%) patient with
a retrograde dissection underwent a composite graft
replacement of the aortic valve, aortic root, and ascending
aorta, with reimplantation of the coronary arteries into the
graft (Bentall procedure).
Technical success was achieved in 100%. Two deaths
occurred after reintervention: one patient died of cirrhosis
at day 20 and another died of an ascending aortic dissection
at 20 months, with a reintervention-related mortality of 7%
(n ¼ 1).
Univariate logistic regression. Results of the univar-
iate logistic regression analysis are reported in Table V. No
statistically signiﬁcant differences were found between the
two groups in age, sex, hypertension, previous aortic
surgery, length of the dissection (limited to the thoracic
aorta or extensive), proportion of acute or chronic dissec-
tion, length of the proximal landing zone, presence of
transposition of the supra-aortic vessels, length of aortic
coverage, and false lumen thrombosis distal to the stent
graft. False lumen thrombosis at the stent graft level was
signiﬁcantly more frequent in patients not requiring rein-
tervention than in those requiring reintervention before
secondary procedure.
Multivariate logistic regression analysis. Multivar-
iate analysis (Table V) demonstrated that proximal over-
sizing $20% (OR, 16; 95% CI, 1.9-137.2; adjusted P ¼
.011), the use of a stent graft with a proximal bare spring
(OR, 12; 95% CI, 1.2-109.3; adjusted P ¼ .032), and
long-term anticoagulant therapy (OR, 78%; CI, 1.5-999.3;
adjusted P ¼ .03) were signiﬁcant predictors for reinter-
vention after TEVAR for C-AD.
Table V. Results of the univariate and multivariate logistic regressions
Variable
Univariate analysisa Multivariate analysisa,b
OR (95% CI) P OR (95% CI) P
Age at ﬁrst TEVAR (for each 5-year increase) 1.0 (0.8-1.3) .39 . .
Male sex 2.4 (0.4-18.2) .39 . .
Hypertension 0.6 (0.1-2.7) .51 . .
Anticoagulant therapy 37 (1.4-966.1) .03 78 (1.5-999.3) .03
Previous aortic surgery 2.4 (0.6-9) .21 . .
Extensive dissection 2 (0.2-15.5) .53 . .
Acute dissection 0.4 (0.1-1.9) .27 . .
Aneurysm diameter (for each 10-mm increase) 1.8 (1.1-3) .029 . .
Proximal landing zone length (for each 5-mm increase) 0.9 (0.6-1.3) .44 . .
Transposition of the supra-aortic vessels 1.0 (0.3-3.8) .98 . .
Stent graft with proximal bare spring 6.3 (1.3-31.3) .024 12 (1.2-109.3) .032
Length of aortic coverage (for each 20-mm increase) 1.0 (0.8-1.2) .95 . .
Proximal oversizing >20% 11 (2.3-55.9) .003 16 (1.9-137.2) .011
Postoperative false lumen thrombosis at stent graft level 70 (3.4-1) .006 . .
Postoperative false lumen thrombosis distal to the stent graft 3.4 (0.5-24.9) .23 . .
CI, Conﬁdence interval; OR, odds ratio.
Risk factors for reintervention are indicated in bold.
aFirth method logistic regression (penalizes likelihood).
bStepwise descending selection method.
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Since the ﬁrst report of TEVAR repair in 1994 by Dake
et al,10 indications for TEVAR have broadened. At present,
due to lower perioperative mortality and morbidity
compared with conventional open repair, the use of
TEVAR11,12 is not limited to treating degenerating aneu-
rysms but is also used for complicated acute or chronic
aortic dissection.13-15 TEVAR has reduced perioperative
mortality by more than two-thirds in the setting of aortic
dissection but is associated with higher reintervention rates
than open repair and TEVAR for degenerative thoracic
aneurysms. Long-term durability for this speciﬁc disease
remains unknown.2
Current published reports suggest that reintervention
rates at up to 5 years seem to be higher for TEVAR for
C-AD (acute and chronic) than TEVAR for thoracic
degenerative aneurysm. Parsa et al16,17 reported rates of
23%, whereas Böckler et al18 reported rates of 32% in the
setting of C-AD, increasing to 46% at 5 years when
TEVAR is performed for acute dissection.7 This compares
to reintervention rates of 15% to 17% after TEVAR for
thoracic aneurysm.5,19 Patterson et al6 recently reported
a lower mortality rate after TEVAR for patients with
chronic dissection (3%) than for patients with aneurysmal
disease (5%). The sample group reported higher reinterven-
tion rates for chronic (29%) or acute aortic dissection (54%)
at 6 years compared with TEVAR for thoracic aortic aneu-
rysm (16%).6 These results may be related to the higher
comorbidity rates in patients with thoracic aortic aneurysm
than in patients treated for aortic dissection and conﬁrm
that outcomes should be analyzed for speciﬁc pathologies
rather than for the type of procedure with the aim of
improving the durability of this technique.
Several publications have reported factors associated
with reintervention after TEVAR for mixed indicationssuch as thoracic aortic disease or thoracic aortic degenera-
tive aneurysm.20 To the best of our knowledge, our study is
the ﬁrst to report the factors of reintervention after TEVAR
for aortic dissection.
In our series of 41 elective patients, we report a 32%
reintervention rate at a mean follow-up of 4.7 years. These
results are quite similar compared with those of the Med-
tronic Thoracic Endovascular Registry (MOTHER).6
However, we report a higher secondary intervention rate
for chronic dissection (38%) than for acute dissection
(20%), although this did not reach statistical signiﬁcance
(P ¼ .2211). This is similar to the report by Böckler
et al18 but contradicts the ﬁnding of the MOTHER, where
acute dissection had a higher reintervention rate of 54% vs
29% at 6 years.6
As reported in other studies, most secondary interven-
tions did not require open surgical repair. In our patients,
all but one secondary intervention was managed by endo-
vascular means. One patient was treated for a retrograde
ascendant aortic dissection. This is a lower rate than the
80% open conversion rate for secondary procedure re-
ported by Neuhauser et al21 (all for type I endoleak) all
for retrograde dissection. Furthermore, no more complica-
tions occurred after reintervention than after primary
procedure, and the reintervention-related death rate was
not higher. We do note that in our practice, the need for
a hybrid procedure with open debranching is common in
the setting of secondary procedures (n ¼ 4 [31%]).
Some authors have mentioned that most retrograde
ascending aortic dissection is associated with the use of
proximal bare-spring stents for endograft treatment of
dissection, with an incidence of 1.33% in the European
Registry on Endovascular Aortic Repair Complications
and 2.48% for Dong et al22 and Eggebrecht H.23 Our
previous study of retrograde ascending aortic dissection
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lighted that aberrant subclavian arteries or aortic arch mal-
formation and stent grafts with proximal bare springs seem
to be associated with retrograde ascending aortic dissec-
tion.24 In particular, careful analysis of our ﬁndings
revealed that the type of device used is a signiﬁcant deter-
minant of TEVAR success in univariate and multivariate
analysis (P ¼ .018). This contrasts with the Lee et al20
results for degenerating thoracic aneurysm, where the
type of device used was not signiﬁcantly associated with
secondary intervention.
This highlights differences in outcomes and complica-
tions according to the pathology being treated. On the
basis of our ﬁndings, the use of stent graft with proximal
bare springs should be avoided in patients with aortic
dissection to decrease the rate of secondary procedures.
Moreover, proximal oversizing $20% appears to be signif-
icantly correlated with the need for reintervention
(Table I). Most instructions for use of the current stent
grafts recommend 10% to 20% oversizing with respect to
the preoperative aortic diameter; however, Dong et al25
did not ﬁnd signiﬁcant differences in oversizing between
patients with and without stent graft-induced new entry
after endovascular repair for Stanford type B aortic dissec-
tion, and there is currently no consensus with regard to
the optimal sizing of stent grafts for TEVAR in the setting
of aortic dissection.25
In our study of patients with reintervention, eight of
the stent grafts placed had a proximal oversizing $20%,
and the four type Ia endoleaks all developed in those
patients with excessive oversizing. One other patient with
30% oversizing later required reintervention for device
migration, and a further patient with 20% oversizing devel-
oped a type Ia endoleak that spontaneously regressed. Our
study suggests that oversizing should be <20% in the
setting of TEVAR for type B dissection to reduce the risk
of complications such as dilatation of the aneurysm neck
with subsequent migration of the endograft or type Ia
endoleak formation leading to reintervention.26
Further analysis of the morphologic characteristics of
the dissections treated in our study showed that the stage
(acute or chronic), extent of the dissection, length of aortic
coverage, length of the proximal landing zone even after
debranching for adequate anchorage, and the status of
the false lumen distal to the stent grafted aorta were not
signiﬁcant factors leading to reintervention (Table V).
However, complete false lumen thrombosis in the region
of the stent grafted aorta seems to be a signiﬁcant anatomic
factor determining TEVAR long-term success (Table V).
We have not shown that the status of the false lumen
thrombosis distally to the stent graft is a signiﬁcant
predictor of outcomes, although most authors agree that
complete false lumen thrombosis is a protective factor pre-
venting aortic growth and death.27,28 Owing to its effect
on thrombogenesis and therefore on false lumen throm-
bosis, long-term anticoagulant therapy is, unsurprisingly,
a signiﬁcant factor in reintervention in this study. Patients
who are receiving long-term anticoagulant therapy forcardiac reasons (auricular ﬁbrillation or a mechanic valve)
should have closer follow-up.
A second signiﬁcant anatomic factor for the long-term
success of TEVAR appears to be the maximal diameter of
the dissected aorta, with a higher risk of reintervention in
case of dilatation leading to form aneurysms (P ¼ .002).
Along the same lines, some have suggested a lower
threshold than an aortic diameter of 5.5 cm for interven-
tion in type B dissection.29,30
As a consequence of the size of our study, the statistical
analysis provided should be interpreted with caution. Our
study points to the need for a specially designed prospective
registry on TEVAR complications for aortic dissection to
clarify the risk factors of reintervention in this speciﬁc area.
CONCLUSIONS
This study conﬁrms the short-term and midterm safety
and feasibility of TEVAR for complicated Stanford type B
dissection. However, the reintervention rate is high
(>30%). Excessive oversizing, the presence of a bare-
spring stent in the proximal landing zone of the stent graft,
dilation to form a large aneurysm, and anticoagulant
therapy appear to be risk factors for reintervention.
Complete false lumen thrombosis seems to be protective.
Anticipating these modiﬁable risk factors for reintervention
appears essential for the long-term durability of TEVAR.
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